Related Experiment Video
Updated: Jan 9, 2026
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Exploring Emerging Therapeutic Targets in Osteosarcoma by Revisiting the Immune and Cancer-Intrinsic Hallmarks of
Lidia Tarone1, Antonella Iacoviello1, Antonino Di Lorenzo1
1Laboratory of OncoImmunology, Molecular Biotechnology Center "Guido Tarone", Department of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Turin, Italy.
Abstract:
Osteosarcoma (OSA) is an aggressive primary bone cancer mainly affecting the pediatric population. Despite intensive multimodal treatments, therapeutic progress has remained limited for decades, resulting in high recurrence rates, poor prognosis driven by metastatic progression, and severe chemotherapy-associated toxicities. To advance the development of more effective and safer therapeutic strategies, our recent studies identified Chondroitin Sulfate Proteoglycan (CSPG)4 as a relevant mediator of the malignant behavior of OSA cells. Targeting CSPG4 DNA-based vaccine demonstrated encouraging antitumor activity against OSA. Nevertheless, since single-agent immunotherapies are often constrained by tumor immune escape, the need for rational combinatorial strategies is of utmost importance. In this perspective, we broaden our analysis to include other potentially complementary targets beyond CSPG4, which may contribute to OSA pathogenesis. Among these, the cystine/glutamate antiporter xCT and Toll-like Receptor 2 (TLR2) emerge as particularly promising due to their established role in tumor progression, therapy resistance, and immune modulation. We discuss the contribution of all these molecules in major hallmarks of OSA-(1) proliferative and survival advantages, (2) metastasis and angiogenesis, and (3) immune evasion-and examine potential strategies for their combined targeting. By leveraging knowledge gained from other cancer models and integrating it with the distinct biological and clinical features of OSA, this perspective seeks to outline rational and innovative combinatorial strategies that may overcome current therapeutic limitations and ultimately improve patient outcomes.
Insights
New research explores targeting multiple molecules, including Chondroitin Sulfate Proteoglycan (CSPG)4, xCT, and Toll-like Receptor 2 (TLR2), to improve osteosarcoma (OSA) treatment. Combining therapies may overcome immune escape and enhance outcomes for this aggressive bone cancer.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Osteosarcoma (OSA) is an aggressive pediatric bone cancer with limited therapeutic progress and high recurrence rates.
- Current treatments face challenges due to chemotherapy toxicity and tumor immune escape.
- Chondroitin Sulfate Proteoglycan (CSPG)4 has been identified as a key mediator of OSA malignancy.
Purpose of the Study:
- To explore novel therapeutic strategies for osteosarcoma by identifying complementary molecular targets beyond CSPG4.
- To investigate the potential of targeting xCT and Toll-like Receptor 2 (TLR2) in combination with CSPG4 for OSA treatment.
- To outline rational combinatorial strategies for osteosarcoma by integrating knowledge from other cancer models.
Main Methods:
- Review and analysis of existing research on CSPG4, xCT, and TLR2 in osteosarcoma pathogenesis.
- Examination of the roles of these molecules in OSA hallmarks: proliferation, survival, metastasis, angiogenesis, and immune evasion.
- Discussion of potential combinatorial targeting strategies based on biological and clinical features of OSA.
Main Results:
- CSPG4 targeting via DNA-based vaccine shows promising antitumor activity in OSA.
- xCT and TLR2 are identified as promising targets due to their roles in tumor progression, therapy resistance, and immune modulation.
- The study highlights the potential of combining therapies targeting CSPG4, xCT, and TLR2 to address OSA hallmarks.
Conclusions:
- Targeting CSPG4, xCT, and TLR2 offers a promising avenue for developing more effective and safer osteosarcoma therapies.
- Combinatorial strategies are crucial to overcome tumor immune escape and improve patient outcomes in osteosarcoma.
- Integrating insights from diverse cancer models can lead to innovative therapeutic approaches for osteosarcoma.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:31The Intrinsic Apoptotic Pathway
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...